Refining method of arginine perindopril

By using a mixed solvent of cyclic carbonate and halogenated alkanes for heating and stirring, combined with the slow cooling and crystallization technology of ether solvents, the problems of increasing impurities, solvent residue and filtration in arginine perindopril are solved, and the problem of difficulty in filtration is achieved. The preparation of high purity and stability products is avoided.

CN118930603APending Publication Date: 2024-11-12SHANDONG KEXIN PHARM CO LTD
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202410998080.8
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2024-07-24
Publication Date
2024-11-12

AI Technical Summary

Technical Problem

In the prior art, there are problems such as enlargement of impurities, excessive solvent residues, difficulty in filtration and tert-butylamine residues of perindopril in the synthesis process of arginine perindopril in the process of synthesis, resulting in unstable product quality and waste.

Method used

The mixture of cyclic carbonate and halogenated alkanes was heated and stirred, and then the ether solvent was added dropwise to slowly cool down and crystallized, and rinsed and dried by solvent to obtain high-purity perindopril arginine.

Benefits of technology

It effectively reduces the content of impurity B, solvent residues and perindopril tert-butylamine residues, improves the purity and stability of the product, solves the problem of filtration difficulties, and realizes the applicability of industrial production.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN118930603A_ABST
    Figure CN118930603A_ABST
Patent Text Reader

Abstract

The invention belongs to the technical field of medicines, and relates to a refining method of arginine perindopril, which comprises the following steps: S1, adding a crude product of arginine perindopril and a mixed solvent of two solvents into a container, stirring and heating, raising the temperature to 30-50 DEG C, and keeping the temperature and stirring; s2, dropwise adding a third solvent into the system, keeping the temperature and stirring for a period of time, slowly cooling to-5 to 5 DEG C, and crystallizing; and S3, filtering, leaching a filter cake with a solvent, and drying to obtain the refined arginine perindopril. The purity of the produced arginine perindopril is greater than or equal to 99%, the impurity B content is 0-0.05%, the content of other simple substances is less than 0.10%, the content of solvent residue is less than 0.5%, and the content is 98.0-102.0%. According to the method, the crystal form is not changed, the gamma crystal form is maintained, and the arginine perindopril can be directly used as a raw material medicine and meets the requirements of preparations.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The invention belongs to the technical field of drug preparation, and particularly relates to a method for refining arginine perindopril. Background Art

[0002] The information disclosed in this background technology section is only intended to enhance the understanding of the overall background of the invention, and should not necessarily be regarded as an admission or any form of suggestion that the information constitutes the prior art known to a person skilled in the art.

[0003] Perindopril is a third-generation angiotensin converting enzyme (ACE) that does not contain a sulfhydryl group. Perindopril can dilate large and small arteries, reduce blood volume, lower systemic vascular resistance, left ventricular filling pressure and pulmonary capillary wedge pressure, increase cardiac output and stroke volume, increase cardiac index without changing heart rate, improve patients' exercise tolerance, reduce left ventricular hypertrophy, and improve hemodynamics. The drug has a long duration of action and good tolerance, does not cause hyperglycemia, and has no adverse effects on blood lipids.

[0004] Perindopril arginine is a drug for the treatment of mild to moderate essential hypertension launched by Servier, France. Compared with perindopril tert-butylamine, the compound is more stable and its shelf life can be extended to more than 2 years. Perindopril arginine can be combined with amlodipine besylate or indapamide to form a compound preparation, which has outstanding efficacy in treating adult patients with hypertension that cannot be adequately controlled by a single drug. The chemical name of perindopril arginine is: (2S,3aS,7aS)-1-[(S)-N-[(S)-1-ethoxycarbonylbutyl]alanyl]octahydro-2-carboxylic acid arginine salt, and its structure is shown in formula (I):

[0005]

[0006] In the prior art, the synthesis of arginine perindopril is usually performed by directly salting perindopril tert-butylamine with arginine or first obtaining free perindopril and then salting with arginine. The existing process has several problems: ① The salting process requires spray drying or high-temperature reflux water separation. If the temperature is too high, it will lead to an increase in impurities, especially a significant increase in degradation impurity B. The structure of impurity B is shown below:

[0007]

[0008] ② In the direct salt formation or release process, incomplete release leads to residual perindopril tert-butylamine, which in turn leads to higher content data of the raw material drug detected in arginine perindopril.

[0009] ③ Existing technologies all have the phenomenon of poor crystallization state and difficult filtration. Some technologies use polar aprotic solvents such as DMSO, DMF, DMA, NMP and other high-boiling point solvents. Although they help to improve the crystallization state, they are difficult to remove. The solvent residue in the obtained product is generally >1.0%, far exceeding the pharmacopoeia limit of ≤0.5%.

[0010] When the method for refining high-purity perindopril provided by the reference patent is repeated, it is found that, unlike perindopril, after adding ethanol or ethyl acetate to perindopril arginine, n-heptane or n-hexane is added dropwise, the system is gel-like, filtration is very difficult, the filter cake agglomerates, and cannot be dried. Even if powdered perindopril arginine is used, it will be gel-like when dissolved with conventional solvents (acetonitrile, ethyl acetate, acetone, etc.), and filtered by crystallization (cyclohexane, n-hexane, n-heptane, etc.), filtration is difficult, and purification is impossible.

[0011] Currently, there is no reported method for refining perindopril arginine, so it is of great significance to find a refining method to solve the defects of the existing technology and improve and ensure the quality of perindopril arginine. Summary of the invention

[0012] In order to make up for the problems of the prior art in the refining of arginine perindopril, and avoid the phenomenon that the system is gel-like and difficult to filter when the perindopril refining method is used to purify arginine perindopril, the present invention provides a refining method of arginine perindopril, which can effectively reduce the content of impurity B, reduce the residual solvent and reduce the residual perindopril tert-butylamine salt, is suitable for industrial production, and the prepared arginine perindopril meets the requirements of the preparation. In order to achieve the above purpose, the present invention provides the following technical scheme:

[0013] A method for refining perindopril arginine comprises the following steps:

[0014] S1: adding crude arginine perindopril and a mixed solvent containing two solvents into a container, stirring and heating, and then keeping the temperature and stirring after heating;

[0015] The mixed solvent is a mixture of cyclic carbonate and halogenated alkane;

[0016] S2: Add the third solvent dropwise into the system, keep warm and stir for a period of time, slowly cool down, and crystallize;

[0017] S3: Filtering, rinsing the filter cake with a solvent, and drying to obtain the refined perindopril arginine.

[0018] In some embodiments, in step S1, in the mixed solvent containing two solvents, the cyclic carbonate is selected from propylene carbonate or ethylene carbonate; and the halogenated alkane is selected from dichloromethane, chloroform or 1,2-dichloroethane.

[0019] In some embodiments, in step S1, the mass volume ratio of the crude perindopril arginine to the mixed solvent is 1:5-10 g / ml, preferably 1:7 g / ml.

[0020] Furthermore, in step S1, the mixed solvent containing two solvents is a mixture of propylene carbonate and dichloromethane, and the use of the mixed solvent improves the solubility.

[0021] In some embodiments, in step S1, the volume ratio of propylene carbonate to dichloromethane in the mixed solvent is 1:0.2-0.7 ml / ml, preferably 1:0.4 g / ml.

[0022] In some embodiments, in step S1, the heating temperature is 30-50°C, preferably 40°C.

[0023] In some embodiments, in step S1, the heat preservation and stirring time is 1 h to 3 h, preferably 2 h.

[0024] In some embodiments, in step S2, the third solvent is an ether solvent selected from one or a mixed solvent of cyclopentyl methyl ether, methyl tert-butyl ether or isopropyl ether, preferably cyclopentyl methyl ether.

[0025] In some embodiments, in step S2, the mass volume ratio of the crude perindopril arginine to the third solvent is 1:10-15 g / ml, preferably 1:12 g / ml.

[0026] In some embodiments, in step S2, the cooling and crystallization temperature is -5 to 5°C, preferably 0°C.

[0027] In some embodiments, in step S2, the crystallization time is 1 to 4 hours, preferably 2 hours.

[0028] In some embodiments, in step S3, the solvent used for washing the filter cake is an ether solvent selected from cyclopentyl methyl ether, methyl tert-butyl ether, isopropyl ether or a mixture of several thereof, preferably cyclopentyl methyl ether.

[0029] In some embodiments, in step S3, the precipitated solid is vacuum dried at 40-60°C for 8-20 h, preferably at 50°C for 12-16 h.

[0030] The purity of the arginine perindopril prepared by the invention is ≥99.0%, the impurity B is 0-0.05%, the other simple substances are less than 0.10%, the solvent residue is less than 0.5%, and the content is 98.0%-102.0%.

[0031] Compared with the prior art, the present invention has the following beneficial effects:

[0032] (1) The prior art does not disclose a purification method for arginine perindopril. Once impurities exceed the limit and the quality is unqualified during the production process, the product cannot be used and can only be discarded, causing waste, and also wasting manpower and material resources. The present invention can effectively remove the degradation impurity B and other impurities, and the yield is greater than 90%, achieving the control of impurity B, ensuring stable and qualified product output, avoiding waste, and improving energy efficiency.

[0033] (2) The present invention utilizes the difference in solubility of perindopril tert-butylamine salt and perindopril arginine salt in halogenated alkanes to effectively remove residual perindopril tert-butylamine and solve the problem of high content. The reason is that the content of perindopril in perindopril tert-butylamine accounts for 83.4%, and the content of perindopril in arginine perindopril accounts for 67.9%. Since the detection of the content of arginine perindopril is based on perindopril salt, if there is residual perindopril tert-butylamine, the content result of arginine perindopril will actually contain perindopril tert-butylamine, so the residual perindopril tert-butylamine in arginine perindopril will lead to high content; at the same time, the API cannot be guaranteed to be stable as described in the background technology section. Therefore, the existing technology cannot effectively control the quality of the API.

[0034] (3) The present invention solves the problem of residual solvents. Dimethyl sulfoxide has a high boiling point and is not easy to remove during drying. The amount detected in the product obtained by the prior art is about 1%, far exceeding the pharmacopoeia limit of ≤0.5%. The present invention uses cyclic carbonate to replace DMSO. Cyclic carbonate has low viscosity, good thermal stability, low vapor pressure, and is easy to remove during drying. After the refined sample, the amount of dimethyl sulfoxide detected is very small or not detected, and the amount of cyclic carbonate detected is <0.1%.

[0035] (4) In the prior art, when different post-treatments are performed, the system will appear gelatinous and difficult to filter. The present invention uses a mixed solvent of propylene carbonate / dichloromethane / cyclopentyl methyl ether in a specific ratio to improve the stirring state, so that the system is in a dispersed state and easy to filter, thereby obtaining white powdered arginine perindopril. If the ratio is exceeded, the refined system will appear gelatinous to varying degrees, resulting in difficulty in filtering.

[0036] (5) The present invention maintains the same crystal form. The characteristic peaks in the diffraction patterns of the crude product and the refined product are consistent, indicating that the crystal form is consistent. It is a γ crystal form before refining and it is still a γ crystal form after refining without any change. It meets the requirements of preparations and can be directly used as a raw material. BRIEF DESCRIPTION OF THE DRAWINGS

[0037] The accompanying drawings in the specification, which constitute a part of the present invention, are used to provide a further understanding of the present invention. The exemplary embodiments of the present invention and their descriptions are used to explain the present invention and do not constitute improper limitations on the present invention.

[0038] Figure 1 Liquid chromatogram of crude perindopril arginine used in the examples and comparative examples;

[0039] Figure 2 The purity after refinement of Example 1;

[0040] Figure 3 The diffraction pattern of the crude arginine perindopril used in the examples and comparative examples;

[0041] Figure 4 This is the diffraction pattern of Example 3 after refinement. DETAILED DESCRIPTION

[0042] It should be noted that the following detailed descriptions are exemplary and are intended to provide further explanation of the present invention. Unless otherwise specified, all technical and scientific terms used herein have the same meanings as those commonly understood by those skilled in the art to which the present invention belongs.

[0043] It should be noted that the terms used herein are only for describing specific embodiments and are not intended to limit exemplary embodiments according to the present invention. As used herein, unless the context clearly indicates otherwise, the singular form is also intended to include the plural form. In addition, it should be understood that when the terms "comprising" and / or "including" are used in this specification, it indicates the presence of features, steps, operations, devices, components and / or combinations thereof.

[0044] The arginine perindopril detection method used in this embodiment is:

[0045] Chromatographic column: Octadecylsilane bonded silica gel as filler (XB-C18, 4.6mm×250mm, 5μm)

[0046] Mobile phase A: water [adjust pH to 3.5 with phosphoric acid solution (1→2)];

[0047] Mobile phase B: phosphoric acid in acetonitrile;

[0048] Flow rate: 1.0ml / min;

[0049] Injection volume: 10 μl;

[0050] Column temperature: 30°C;

[0051] Solvent: Water [adjust pH to 3.5 with phosphoric acid solution (1→2);

[0052] Detection wavelength: 215nm;

[0053] Running time: 75 minutes.

[0054] Perform gradient elution according to the following table:

[0055] Time (minutes) Mobile phase A (%) Mobile phase B (%) 0 90 10 10 90 10 30 70 30 45 65 35 60 20 80 68 20 80 69 90 10 75 90 10

[0056] Test operation:

[0057] Test sample solution: Take about 20 mg of the test sample, weigh accurately, place in a 10 ml volumetric flask, add solvent to dissolve and dilute to the scale, and shake well.

[0058] Accurately measure 10 μl of the solvent and the above solution, inject them into the liquid chromatograph respectively, and record the chromatogram.

[0059] Embodiment 1:

[0060] The arginine perindopril purification method of the present embodiment comprises the following steps:

[0061] S1: Start stirring and add 10 g of crude arginine perindopril (chromatogram as shown in Figure 1 As shown, the diffraction pattern is Figure 3 As shown), 50 ml of propylene carbonate and 10 ml of dichloromethane were added into a three-necked flask, heated to 40°C and stirred for 2 h.

[0062] S2: Add 100 ml of cyclopentyl methyl ether dropwise into the system, control the temperature to >30°C, and after the addition is complete, stir and keep warm for 0.5 h, slowly cool the cold trap to 0°C, and crystallize for 1 h.

[0063] S3: Filter, rinse the filter cake with 20 ml of cold cyclopentyl methyl ether, and dry the filter cake at 50°C in vacuum for 12 h to obtain 9.2 g of white powdered perindopril arginine. Figure 2 shown.

[0064] Embodiment 2:

[0065] The arginine perindopril purification method of the present embodiment comprises the following steps:

[0066] S1: Start stirring, add 80 g crude arginine perindopril, 500 ml propylene carbonate and 300 ml dichloromethane into a three-necked flask, heat to 40°C and stir for 2 h.

[0067] S2: Add 1200 ml of cyclopentyl methyl ether dropwise into the system, and control the temperature to >30°C. After the addition is complete, stir and keep warm for 1 hour, and slowly cool the cold trap to 0°C and crystallize for 2 hours.

[0068] S3: Filter, rinse the filter cake with 200 ml of cold cyclopentyl methyl ether, and dry the filter cake in vacuum at 50°C for 12 h to obtain 73.2 g of white powdered perindopril arginine.

[0069] Embodiment 3:

[0070] The arginine perindopril purification method of the present embodiment comprises the following steps:

[0071] S1: Start stirring, add 600 g crude arginine perindopril, 3000 ml propylene carbonate and 1200 ml dichloromethane into a three-necked flask, heat to 40° C., and stir for 2 h.

[0072] S2: Add 7200 ml of cyclopentyl methyl ether dropwise into the system, control the temperature to >30°C, and after the addition is complete, stir and keep warm for 1.5 hours, slowly cool the cold trap to 0°C, and crystallize for 2 hours.

[0073] S3: Filter, rinse the filter cake with 1000 ml of cold cyclopentyl methyl ether, and dry the filter cake in vacuum at 50°C for 14 h to obtain 550.1 g of white powdered perindopril arginine. Figure 4 As shown.

[0074] Figure 3 The crude product showed characteristic peaks at 2θ angles of 7.8°, 14.1°, 17.6°, and 20.1°. Figure 4 The refined product showed characteristic peaks at 2θ angles of 7.8°, 14.1°, 17.6°, and 20.1°. The characteristic peaks in the diffraction patterns of the crude product and the refined product were consistent, indicating that the crystal form was consistent and had not changed. It was γ crystal form before refining and it was still γ crystal form after refining.

[0075] Comparative Example 1:

[0076] 1. Synthesis of Arginine Perindopril

[0077] Preparation: In a reaction bottle, add 10g of tert-butylamine perindopril, 3.8g of L-arginine, and 30ml of water, stir to dissolve, add 100ml of dimethyl sulfoxide, heat to 45°C, evacuate with a water pump, maintain negative pressure, stir to react for 1 hour, then add 50ml of ethyl acetate, cool to 10°C, stir and crystallize for 4 hours, filter, rinse the filter cake with ethyl acetate, and vacuum dry the filter cake (50°C, 12h) to obtain 7.2g of solid. The solid is then slurried twice with 20ml of ethyl acetate, filtered, rinsed, and the filter cake is vacuum dried (50°C, 12h) to obtain 4.0g of arginine perindopril.

[0078] Comparative Example 2

[0079] 1. Synthesis of Arginine Perindopril

[0080] Preparation of perindopril: To a reaction flask, add 30 g of tert-butylamine perindopril and 120 ml of water, stir to dissolve, add 120 ml of dichloromethane, stir at room temperature, add 2.0 mol / L hydrochloric acid dropwise, adjust the pH of the aqueous phase to 4.0, stir for 0.5 h, separate the liquids, dry the dichloromethane phase, filter, and concentrate to obtain perindopril.

[0081] Preparation of Perindopril Arginine: To a reaction flask, add 10.0 g Perindopril, 4.8 g L-arginine, and 40 ml water, stir to dissolve, filter, and dropwise add 120 ml of dimethyl sulfoxide to the filtrate. After the addition is complete, cool to 20°C, keep warm and stir for 1 hour, filter, and wash the filter cake with 100 ml of acetone and 100 ml of n-heptane in turn. The filter cake is vacuum dried (50°C, 12 hours) to obtain 5.3 g Perindopril Arginine.

[0082] Comparative Example 3:

[0083] 1. Refining of arginine perindopril (reducing the amount of cyclopentyl methyl ether to 5g / ml):

[0084] In a reaction bottle, add 10g of arginine perindopril, 50ml of propylene carbonate and 50ml of dichloromethane into a three-necked flask, heat to 40°C, stir for 2h, add 50ml of cyclopentyl methyl ether dropwise into the system, control the temperature to >30°C, after the addition is complete, keep warm and stir for 0.5h, slowly cool to 0°C in a cold trap, crystallize for 2h, the system is viscous and gel-like, and filtration is very difficult. The system is viscous and gel-like, and filtration is very difficult. The experiment failed and no product was obtained.

[0085] Conclusion: After reducing the amount of cyclopentyl methyl ether, the stirring state of the refining system is very poor, it is in a gel state and difficult to filter.

[0086] Comparative Example 4:

[0087] 1. Refining of arginine perindopril (increasing the amount of dichloromethane):

[0088] In a reaction flask, add 10g of crude arginine perindopril, 50ml of propylene carbonate, and 50ml of dichloromethane into a three-necked flask, heat to 40°C, stir for 2h, add 120ml of cyclopentyl methyl ether dropwise to the system, control the temperature to >30°C, after the addition is complete, keep warm and stir for 0.5h, slowly cool to 0°C in a cold trap, crystallize for 2h, filter, rinse the filter cake with cold 20ml of cyclopentyl methyl ether, and dry the filter cake in vacuum at 50°C for 14h to obtain 6.5g of white powder arginine perindopril, with a yield of 65.0%.

[0089] Conclusion: After increasing the amount of dichloromethane, the yield decreased by 25% and the product loss was large.

[0090] Comparative Example 5:

[0091] 1. Refining of arginine perindopril (using isopropyl ether):

[0092] In a reaction flask, add 10g of crude arginine perindopril, 50ml of propylene carbonate, and 28ml of dichloromethane into a three-necked flask, heat to 40°C, stir for 2h, add 120ml of isopropyl ether dropwise to the system, control the temperature to >30°C, after the addition is complete, keep warm and stir for 0.5h, slowly cool to 0°C in a cold trap, crystallize for 2h, filter, filter slowly, the filter cake is slightly lumpy, rinse with cold 20ml of isopropyl ether, and dry the filter cake in vacuum at 50°C for 14h to obtain 9.2g of white powder arginine perindopril, with a yield of 92.0%.

[0093] Conclusion: After switching to isopropyl ether, the filtration speed slowed down, the filter cake showed agglomeration, and a white solid was obtained instead of a white powder, which was slightly worse than the product obtained with cyclopentyl methyl ether.

[0094]

[0095] Comparative Examples 1 and 2 cannot avoid the problem of high detected content of perindopril arginine salt due to perindopril tert-butylamine, which affects the accuracy of the test results.

[0096] Impurity B in this method is a chromatographic peak with a retention time of about 42 minutes, such as Figure 1 As shown in FIG. 1 , the impurity B content in the crude product is about 0.45%, while the impurity B content in the arginine perindopril after purification by Example 1 of the method of the present invention is as follows: Figure 2 As shown, it is about 0.01%; the impurity B content of the methods provided in Comparative Examples 1 and 2 is higher than 0.1%, which shows that the method cannot achieve effective control of impurity B; in addition, the residual dimethyl sulfoxide is relatively high.

[0097] In summary, it can be seen that the method provided by the present invention can significantly reduce the content of dimethyl sulfoxide and the content of impurity B, improve the purity of the product, and avoid the problem of high content of perindopril arginine salt detected due to the presence of perindopril tert-butylamine.

[0098] In addition, the present invention uses a mixed solvent of propylene carbonate / dichloromethane / cyclopentyl methyl ether in a specific ratio to improve the stirring state, so that the system is in a dispersed state, and filtration is easy to obtain white powdery arginine perindopril. If the ratio is beyond the range, the refined system will appear gel to varying degrees, resulting in difficulty in filtration.

[0099] The above description is only a preferred embodiment of the present invention and is not intended to limit the present invention. For those skilled in the art, the present invention may have various modifications and variations. Any modification, equivalent replacement, improvement, etc. made within the spirit and principle of the present invention shall be included in the protection scope of the present invention.

Claims

1. A method for refining perindopril arginine, characterized in that: The steps include: S1: adding crude arginine perindopril and a mixed solvent containing two solvents into a container, stirring and heating, and then keeping the temperature and stirring after heating; The mixed solvent is a mixture of cyclic carbonate and halogenated alkane; S2: Add the third solvent dropwise into the system, keep warm and stir for a period of time, slowly cool down, and crystallize; S3: Filtering, rinsing the filter cake with a solvent, and drying to obtain the refined perindopril arginine.

2. The refining method according to claim 1, characterized in that In step S1, in the mixed solvent containing two solvents, the cyclic carbonate is selected from propylene carbonate or ethylene carbonate; the halogenated alkane is selected from dichloromethane, chloroform or 1,2-dichloroethane.

3. The purification method according to claim 1, characterized in that: In step S1, the mass volume ratio of the crude perindopril arginine to the mixed solvent is 1:5-10 g / ml.

4. The refining method according to claim 1, characterized in that: In step S1, the mixed solvent containing two solvents is a mixture of propylene carbonate and dichloromethane.

5. The refining method according to claim 4, characterized in that: In step S1, the volume ratio of propylene carbonate to dichloromethane in the mixed solvent is 1:0.2-0.7 ml / ml.

6. The purification method according to claim 1, characterized in that: In step S1, the heating temperature is 30-50°C; the heat preservation and stirring time is 1h-3h.

7. The purification method according to claim 1, characterized in that: In step S2, the third solvent is an ether solvent selected from one or a mixed solvent of cyclopentyl methyl ether, methyl tert-butyl ether or isopropyl ether.

8. The purification method according to claim 1, characterized in that: In step S2, the mass volume ratio of the crude perindopril arginine to the third solvent is 1:10-15 g / ml.

9. The purification method according to claim 1, characterized in that: In step S2, the crystallization temperature is lowered to -5 to 5°C; In step S2, the crystallization time is 1 to 4 hours; In step S3, the precipitated solid is dried under vacuum at 40-60° C. for 8-20 h.

10. The purification method according to claim 1, characterized in that: In step S3, the solvent used for washing the filter cake is an ether solvent selected from cyclopentyl methyl ether, methyl tert-butyl ether, isopropyl ether or a mixture of several thereof.